Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: PHB2

Gene summary for PHB2

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

PHB2

Gene ID

11331

Gene nameprohibitin 2
Gene AliasBAP
Cytomap12p13.31
Gene Typeprotein-coding
GO ID

GO:0000003

UniProtAcc

Q99623


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
11331PHB2HTA11_3410_2000001011HumanColorectumAD1.13e-083.65e-010.0155
11331PHB2HTA11_2487_2000001011HumanColorectumSER1.54e-116.33e-01-0.1808
11331PHB2HTA11_2951_2000001011HumanColorectumAD4.61e-036.33e-010.0216
11331PHB2HTA11_1938_2000001011HumanColorectumAD6.28e-115.66e-01-0.0811
11331PHB2HTA11_78_2000001011HumanColorectumAD1.15e-187.79e-01-0.1088
11331PHB2HTA11_347_2000001011HumanColorectumAD1.10e-431.03e+00-0.1954
11331PHB2HTA11_411_2000001011HumanColorectumSER2.09e-026.63e-01-0.2602
11331PHB2HTA11_3361_2000001011HumanColorectumAD8.53e-137.69e-01-0.1207
11331PHB2HTA11_83_2000001011HumanColorectumSER2.79e-075.12e-01-0.1526
11331PHB2HTA11_696_2000001011HumanColorectumAD6.95e-286.35e-01-0.1464
11331PHB2HTA11_866_2000001011HumanColorectumAD2.30e-206.06e-01-0.1001
11331PHB2HTA11_1391_2000001011HumanColorectumAD7.68e-247.81e-01-0.059
11331PHB2HTA11_2992_2000001011HumanColorectumSER8.93e-056.13e-01-0.1706
11331PHB2HTA11_5212_2000001011HumanColorectumAD3.56e-064.49e-01-0.2061
11331PHB2HTA11_5216_2000001011HumanColorectumSER2.64e-026.12e-01-0.1462
11331PHB2HTA11_546_2000001011HumanColorectumAD1.19e-107.77e-01-0.0842
11331PHB2HTA11_9341_2000001011HumanColorectumSER4.88e-035.17e-01-0.00410000000000005
11331PHB2HTA11_866_3004761011HumanColorectumAD1.11e-246.81e-010.096
11331PHB2HTA11_4255_2000001011HumanColorectumSER5.98e-118.28e-010.0446
11331PHB2HTA11_8622_2000001021HumanColorectumSER6.56e-076.04e-010.0528
Page: 1 2 3 4 5 6 7 8 9 10 11 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
Colorectum (GSE201348)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.FAP: Familial adenomatous polyposis
CRC: Colorectal cancer
Colorectum (HTA11)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AD: Adenomas
SER: Sessile serrated lesions
MSI-H: Microsatellite-high colorectal cancer
MSS: Microsatellite stable colorectal cancer
EndometriumThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AEH: Atypical endometrial hyperplasia
EEC: Endometrioid Cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:00105635ColorectumCRCnegative regulation of phosphorus metabolic process68/2078442/187233.33e-032.85e-0268
GO:00510513ColorectumCRCnegative regulation of transport71/2078470/187234.33e-033.47e-0271
GO:00336734ColorectumCRCnegative regulation of kinase activity40/2078237/187234.58e-033.57e-0240
GO:00485683ColorectumCRCembryonic organ development65/2078427/187235.15e-033.94e-0265
GO:00465801ColorectumCRCnegative regulation of Ras protein signal transduction12/207849/187236.21e-034.54e-0212
GO:0090596ColorectumCRCsensory organ morphogenesis42/2078256/187236.22e-034.54e-0242
GO:0021953ColorectumCRCcentral nervous system neuron differentiation29/2078162/187236.36e-034.62e-0229
GO:00423265ColorectumCRCnegative regulation of phosphorylation59/2078385/187236.45e-034.67e-0259
GO:00519621ColorectumCRCpositive regulation of nervous system development44/2078272/187236.71e-034.77e-0244
GO:00071622ColorectumCRCnegative regulation of cell adhesion48/2078303/187237.14e-034.96e-0248
GO:001603216EndometriumAEHviral process110/2100415/187231.99e-181.09e-15110
GO:000609110EndometriumAEHgeneration of precursor metabolites and energy121/2100490/187231.65e-178.23e-15121
GO:003164716EndometriumAEHregulation of protein stability77/2100298/187231.13e-122.26e-1077
GO:005082116EndometriumAEHprotein stabilization55/2100191/187232.19e-113.20e-0955
GO:000989616EndometriumAEHpositive regulation of catabolic process104/2100492/187239.38e-111.10e-08104
GO:004440316EndometriumAEHbiological process involved in symbiotic interaction70/2100290/187233.26e-103.55e-0870
GO:003133116EndometriumAEHpositive regulation of cellular catabolic process91/2100427/187239.15e-108.31e-0891
GO:004854516EndometriumAEHresponse to steroid hormone76/2100339/187232.15e-091.77e-0776
GO:007259410EndometriumAEHestablishment of protein localization to organelle89/2100422/187232.41e-091.90e-0789
GO:005170116EndometriumAEHbiological process involved in interaction with host53/2100203/187232.48e-091.93e-0753
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
EFNA5EPHB2EFNA5_EPHB2EPHACervixCC
EFNB1EPHB2EFNB1_EPHB2EPHBCervixCC
EFNB2EPHB2EFNB2_EPHB2EPHBCervixCC
EFNB1EPHB2EFNB1_EPHB2EPHBCRCAD
EFNB2EPHB2EFNB2_EPHB2EPHBCRCAD
EFNA5EPHB2EFNA5_EPHB2EPHACRCAD
EFNA5EPHB2EFNA5_EPHB2EPHACRCADJ
EFNB1EPHB2EFNB1_EPHB2EPHBCRCADJ
EFNB2EPHB2EFNB2_EPHB2EPHBCRCADJ
EFNA5EPHB2EFNA5_EPHB2EPHACRCCRC
EFNB2EPHB2EFNB2_EPHB2EPHBCRCCRC
EFNA5EPHB2EFNA5_EPHB2EPHACRCFAP
EFNB2EPHB2EFNB2_EPHB2EPHBCRCFAP
EFNA5EPHB2EFNA5_EPHB2EPHACRCHealthy
EFNB2EPHB2EFNB2_EPHB2EPHBCRCHealthy
EFNA5EPHB2EFNA5_EPHB2EPHACRCMSI-H
EFNB1EPHB2EFNB1_EPHB2EPHBCRCMSI-H
EFNB2EPHB2EFNB2_EPHB2EPHBCRCMSI-H
EFNB1EPHB2EFNB1_EPHB2EPHBCRCMSS
EFNB2EPHB2EFNB2_EPHB2EPHBCRCMSS
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
PHB2SNVMissense_Mutationc.896A>Cp.Lys299Thrp.K299TQ99623protein_codingdeleterious_low_confidence(0)benign(0.143)TCGA-EW-A1PE-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapyfluorouracilSD
PHB2insertionFrame_Shift_Insnovelc.377_378insATTGGGAATTAp.Asp127LeufsTer31p.D127Lfs*31Q99623protein_codingTCGA-A8-A08T-01Breastbreast invasive carcinomaFemale<65III/IVUnknownUnknownPD
PHB2SNVMissense_Mutationc.415N>Cp.Glu139Glnp.E139QQ99623protein_codingdeleterious(0)probably_damaging(1)TCGA-IR-A3LA-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinCR
PHB2insertionFrame_Shift_Insnovelc.44_45insCCCATp.Arg17CysfsTer9p.R17Cfs*9Q99623protein_codingTCGA-A6-6653-01Colorectumcolon adenocarcinomaMale>=65I/IIUnknownUnknownSD
PHB2insertionFrame_Shift_Insnovelc.43_44insTp.Gly15ValfsTer68p.G15Vfs*68Q99623protein_codingTCGA-A6-6653-01Colorectumcolon adenocarcinomaMale>=65I/IIUnknownUnknownSD
PHB2SNVMissense_Mutationrs782150944c.368G>Ap.Arg123Hisp.R123HQ99623protein_codingtolerated(0.14)benign(0.013)TCGA-A5-A0G2-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVUnknownUnknownSD
PHB2SNVMissense_Mutationc.283N>Tp.Gly95Cysp.G95CQ99623protein_codingdeleterious(0)probably_damaging(0.995)TCGA-AP-A051-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
PHB2SNVMissense_Mutationnovelc.754C>Tp.Arg252Cysp.R252CQ99623protein_codingdeleterious(0)probably_damaging(1)TCGA-AX-A2HC-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapypaclitaxelPD
PHB2SNVMissense_Mutationnovelc.895A>Cp.Lys299Glnp.K299QQ99623protein_codingdeleterious_low_confidence(0.01)benign(0.146)TCGA-AX-A2IO-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIChemotherapycarboplatinSD
PHB2SNVMissense_Mutationc.196N>Cp.Glu66Glnp.E66QQ99623protein_codingdeleterious(0.02)probably_damaging(0.992)TCGA-B5-A11R-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIChemotherapypaclitaxelSD
Page: 1 2 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
11331PHB2CELL SURFACESTEROID HORMONE10850416
Page: 1